Status of OliX's research on macular degeneration treatment/Graphic=Yoon Sun-jung OliX is focusing on securing global ...

The obstructive sleep apnea competitive landscape report delivers important insights into approved as well as ongoing research on 22+ pipeline obstructive sleep apnea drugs, clinical strategies, ...

Most AI drug development firms are focused on discovery. AI biotech Formation Bio is betting the real bottleneck is clinical ...

On October 22, 2026 – HUYABIO International announced positive Phase 3 results for its HDAC inhibitor HBI-8000 (tucidinostat) ...

A new bipartisan bill aims to speed rare disease drug development by making clinical trials faster, cheaper and more accessible to patients.

Formation Bio plans to source Phase I and Phase II assets from biotechnology and pharmaceutical companies.

Calls have emerged for a comprehensive redesign of the drug development system as delays in global Phase 2 and 3 clinical ...

The TGFb inhibitor clinical trial analysis report delivers important insights into ongoing research on 30+ TGFb inhibitors in the pipeline, clinical strategies, upcoming therapeutics, and commercial ...

Researchers at Moffitt Cancer Center say identifying and selecting participants for phase II cancer clinical trials from a centralized warehouse of patient-donated biological data expedites ...

Findings from early-phase clinical research conducted with participation from Florida Cancer Specialists & Research Institute ...

Readers respond to a guest essay about the costs and delays in getting experimental treatments to patients. To the Editor: Re “Doctors Who Discover Miracle Cures Worry About Medicine’s Future,” by ...

Experic, a contract development and manufacturing organization (CDMO) specializing in drug product development, manufacturing ...